Navel radiation technologies for malignant gliomas

Current Opinion in Oncology

Volumn 11, Issue 3, 1999, Pages 147-151

  Shafman, Timothy D ^a   Loeffler, Jay S ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN TUMOR; CANCER SURVIVAL; GLIOBLASTOMA; HUMAN; IMAGING; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; TECHNOLOGY; BRACHYTHERAPY; GLIOMA; RADIATION DOSE FRACTIONATION; RADIOIMMUNOTHERAPY; RADIOSURGERY;

RADIOSENSITIZING AGENT;

BRACHYTHERAPY; BRAIN NEOPLASMS; DOSE FRACTIONATION; GLIOMA; HUMANS; RADIATION-SENSITIZING AGENTS; RADIOIMMUNOTHERAPY; RADIOSURGERY;

EID: 0032588517     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199905000-00001     Document Type: Review

References (39)

1. Burger PC, Dubois PJ, Schold SC, Smith KR, Odom GL, Crafts DC, Giangaspero F: Computerized tomographic and pathologic studies of untreated, quiescent and recurrent glioblastoma multiforme. J Neurosurg 1983, 58:159-169.
2. Kelly PJ, Daumas-Duport C, Scheitauer BW, Kispert DB: Stereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clin Proc 1987, 62:450-459.
3. Hochberg FH, Pruitt A: Assumptions in the radiotherapy of glioblastoma. Neurology 1980, 30:907-911.
4. Wallner KE, Galicich JH, Krol G, Arbit E, Malkin MG: Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 1989, 16:1405-1409.
5. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, et al.: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980, 303:1323-1329.
6. Leibel SA, Sheline GE: Tolerance of the central and peripheral nervous system to therapeutic radiation. In Advances in Radiation Biology. Edited by Lett JT, Altman KL. New York: Academic Press; 1987:257-258.
7. Phillips MH, Stelzer KJ, Griffin TW, Mayberg MR, Winn HR: Stereotactic radiosurgery: A review and comparisons of methods. J Clin Oncol 1994, 12:1085-1099.
8. Verhey LJ, Smith V, Serago CF: Comparison of radiosurgery treatment modalities based on physical dose distributions. Int J Radiat Oncol Biol Phys 1998, 40:497-505.
9. Smith V, Verhey L, Serago CF: Comparison of radiosurgery treatment modalities based on complication and control probabilities. Int J Radiat Oncol Biol Phys 1998, 40:507-513.
10. Kondziolka D, Flickinger JC, Bissonette DJ, Bozik M, Lunsford LD: Survival benefit of stereotactic radiosurgery for patients with malignant glial neoplasms. Neurosurgery 1997, 41:776-783.
11. Masciopinto JE, Levin AB, Mehta MP, Rhode BS: Stereotactic radiosurgery for glioblastoma: a final report of 31 patients. J Neurosurg 1995, 82:530-535.
12. Loeffler JS, Alexander E III, Shea WM, Wen PY, Fine HA, Kooy HM, Black PM: Radiosurgery as part of the initial management of patients with malignant gliomas. J Clin Oncol 1992, 10:1379-1385.
13. Shrieve DC, Alexander EA III, Black PM, Wen PY, Kooy HM, Loeffler JS: Treatment of primary glioblastoma multiforme with standard radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. J Neurosurg 1999, in press. This retrospective review updates the long-term follow-up of patients treated with radiosurgery as part of the treatment of newly diagnosed malignant gliomas.
14. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al.: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993, 85:704-710.
15. Sarkaria JN, Mehta MP, Loeffler JS, Buatti JM, Chappell RJ, Levin AB, et al.: Radiosurgery in the initial management of malignant gliomas: survival comparison with the RTOG recursive partitioning analysis. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1995, 32:931-941.
16. Cosgrove GR, Hochberg FH, Zervas NT, Pardo FS, Valenzuela RF, Chapman P: Interstitial irradiation of brain tumors, using a miniature radiosurgery device: initial experience. Neurosurgery 1997, 40:518-523.
17. Fitzek M, Thornton A, Rabenow J, Lev M, Pardo F, Bussiere M, et al.: Results of 90 Gy proton/photon radiation therapy for glioblastoma multiforme. J Neurosurg 1999, in press. This article reports results of a trial of extremely high-dose radiation for malignant gliomas using protons and accelerated hyperfractionation.
18. Loeffler JS, Alexander E III, Hochberg FH, Wen PY, Morris JH, Schoene WC, et al.: Clinical patterns of failure following stereotactic interstitial irradiation for malignant gliomas. Int J Radiat Oncol Biol Phys 1990, 19:1455-1462.
19. Cardinale RM, Schmidt-Ullrich RK, Benedict SH, Zwicker RD, Han DC, Broaddus WC: Accelerated radiotherapy regimen for malignant gliomas using stereotactic concomitant boosts for dose escalation. Radiat Oncol Invest 1998, 6:175-181.
20. McDermott MW, Sneed PK, Gutin PH: Interstitial brachytherapy for malignant brain tumors. Semin Surg Oncol 1998, 14:79-87. This is a thorough review of the use of brachytherapy in the treatment of malignant gliomas.
21. Sneed PK, Prados MD, McDermott MW, Larson DA, Malec MK, Lamborn KR, et al.: Large effect of age on the survival of patients with glioblastoma treated with radiotherapy and brachytherapy boost. Neurosurgery 1995, 36:898-903.
22. Wen PY, Alexander E 3rd, Black PM, Fine HA, Riese N, Levin JM, et al.: Long term results of stereotactic brachytherapy used in the initial treatment of patients with glioblastomas. Cancer 1994, 73:3029-3036.
23. Kinsella TJ, Mitchell JB, Russo A, Morstyn G, Glatstein E: The use of halo-genated thymidine analogs as clinical radiosensitizers: Rationale, current status, and future prospects: non-hypoxic cell sensitizers. Int J Radiat Oncol Biol Phys 1984, 10:1399-1406.
24. Wang Y, Pantelias GE, Iliakis G: Mechanism of radiosensitization by halo-genated pyrimidines: the contribution of excess DNA and chromosome damage in BrdU radiosensitization may be minimal in plateau-phase cells. Int J Radiat Oncol Biol Phys 1994, 66:133-142.
25. Prados MD, Scott CB, Rotman M, Rubin P, Murray K, Sause W, et al.: Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 1998, 40:653-659.
26. Coleman CN, Bump EA, Kramer RA: Chemical modifiers of cancer treatment. J Clin Oncol 1988, 6:709-733.
27. Riese NE, Loeffler JS, Wen P, Alexander E 3rd, Black PM, Coleman CN: A phase I study of etanidazole and radiotherapy in malignant glioma. Int J Radiat Oncol Biol Phys 1994, 29:617-620.
28. Chang EL, Loeffler JS, Riese NE, Wen PY, Alexander E 3rd, Black PM, Coleman CN: Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma. Int J Radiat Oncol Biol Phys 1998, 40:65-70.
29. Brown JM, Wang L: Tirapazamine: laboratory data relevant to clinical activity. Anticancer Drug Des 1998, 13:529-539.
30. Del Rowe J, Scott C, Werner-Wasik M, Baharary JP, Curan WJ, Urtasun RC, Fisher B: A single-arm open label phase II study of intravenously administered tirapazamine for glioblastoma multiforme-an RTOG study. Int J Radiat Oncol Biol Phys 1998, 42(suppl 1):266.
31. Snelling L, Miyamoto CT, Bender H, Brady LW, Steplewski Z, Class R, et al.: Epidermal growth factor receptor 425 monoclonal antibodies radiolabeled with iodine-125 in the adjuvant treatment of high-grade astrocytomas. Hybridoma 1995, 14:111-114.
32. Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, et al.: Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol 1998, 16:2202-2212. This study reports the results of a phase I trial of intracavitary radioimmunotherapy for malignant gliomas with interesting subgroup survival data.
33. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, et al.: Amplification and overexpression of the EGF receptor gene in primary human glioblastomas. J Cell Sci 1985, 3(suppl):161-172.
34. Brady LW, Miyamoto C, Woo DV, Rackover M, Emrich J, Bender H, et al.: Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. Int J Radiat Oncol Biol Phys 1992, 22:225-230.
35. Bourdon MA, Wikstrand CJ, Furthmayr H, Matthews TJ, Bigner DD: Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res 1983, 43:2796-27805.
36. Barker FG 2nd, Chang SM, Gutin PH, Malec MK, McDermott MW, Prados MD, Wilson C: Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 1998, 42:709-720.
37. Shrieve DC, Alexander E 3rd, Wen PY, Fine HA, Kooy HM, Black PM, Loeffler J: Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery 1995, 36:275-282.
38. Liang BC, Weil M: Local regional approaches to therapy with gliomas as the paradigm. Curr Opin Oncol 1998, 10:201-206.
39. Weichselbaum RR, Hallahan DE, Beckett MA, Mauceri HJ, Lee H, Sukhatme VP, Kufe DW: Gene therapy targeted by radiation preferentially radiosensitizes tumor cells. Cancer Res 1994, 54:4266-4269.